Ideas

Ribonucleic acid-based therapy for myocardial diseases: LncRNA FEZF1-AS1-based therapy for Cardiac repair and myocardial infarction: LncRNA  TUG1 increases Agrin expression, activates Yap and ERK-mediated signaling,  replaces scar tissue with functional cardiomyocytes, and promotes cardiomyocyte regeneration and repair after myocardial infarction, via up-regulation of its target gene, 21/February/2019, 12.48 am
Ribonucleic acid-based therapy for myocardial diseases: LncRNA FEZF1-AS1-based therapy for Cardiac repair and myocardial infarction: LncRNA  TUG1 increases Agrin expression, activates Yap and ERK-mediated signaling,  replaces scar tissue with functional cardiomyocytes, and promotes cardiomyocyte regeneration and repair after myocardial infarction, via up-regulation of its target gene, 21/February/2019, 12.48 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A recent study from Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot 76100, Israel; Department of Biomedical Engineering, Duke University, Durham, North Carolina 27708,…

read more

Molecular hydrogen-based therapy for arthritis: High-content hydrogen water (HHW) increases IL-9 levels, augments proliferation of ILC2s (type 2 innate lymphoid cells) and regulatory T (Treg) cells, promotes resolution of inflammation, attenuates cartilage destruction, decreases bone loss, and inhibits pathological features associated with arthritis via up-regulation of its target genes, 21/February/2019, 12.39 am
Molecular hydrogen-based therapy for arthritis: High-content hydrogen water (HHW) increases IL-9 levels, augments proliferation of ILC2s (type 2 innate lymphoid cells) and regulatory T (Treg) cells, promotes resolution of inflammation, attenuates cartilage destruction, decreases bone loss, and inhibits pathological features associated with arthritis via up-regulation of its target genes, 21/February/2019, 12.39 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from Department of Internal Medicine 3-Rheumatology and Immunology, Friedrich Alexander University Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany shows that “Resolution of inflammation by…

read more

Ribonucleic acid-based therapy for myocardial diseases: LncRNA TNK-AS1-based therapy for Cardiac repair and myocardial infarction: LncRNA  TUG1 increases Agrin expression, activates Yap and ERK-mediated signaling,  replaces scar tissue with functional cardiomyocytes, and promotes cardiomyocyte regeneration and repair after myocardial infarction, via up-regulation of its target gene, 21/February/2019, 12.29 am
Ribonucleic acid-based therapy for myocardial diseases: LncRNA TNK-AS1-based therapy for Cardiac repair and myocardial infarction: LncRNA  TUG1 increases Agrin expression, activates Yap and ERK-mediated signaling,  replaces scar tissue with functional cardiomyocytes, and promotes cardiomyocyte regeneration and repair after myocardial infarction, via up-regulation of its target gene, 21/February/2019, 12.29 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A recent study from Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot 76100, Israel; Department of Biomedical Engineering, Duke University, Durham, North Carolina 27708,…

read more

Repurposing the lipid-lowering drug Fenofibrate into an anti-arthritic drug: Fenofibrate (brand name:Antara, Fenoglide, Fibricor, Lipofen, Lofibra, Tricor, Triglide, Trilipix) increases IL-9 levels, augments proliferation of ILC2s (type 2 innate lymphoid cells) and regulatory T (Treg) cells, promotes resolution of inflammation, attenuates cartilage destruction, decreases bone loss, and inhibits pathological features associated with arthritis via up-regulation of its target genes, 21/February/2019, 12.23 am
Repurposing the lipid-lowering drug Fenofibrate into an anti-arthritic drug: Fenofibrate (brand name:Antara, Fenoglide, Fibricor, Lipofen, Lofibra, Tricor, Triglide, Trilipix) increases IL-9 levels, augments proliferation of ILC2s (type 2 innate lymphoid cells) and regulatory T (Treg) cells, promotes resolution of inflammation, attenuates cartilage destruction, decreases bone loss, and inhibits pathological features associated with arthritis via up-regulation of its target genes, 21/February/2019, 12.23 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from Department of Internal Medicine 3-Rheumatology and Immunology, Friedrich Alexander University Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany shows that “Resolution of inflammation by…

read more

Molecular therapy for attenuating pathogenesis-associated with Myocardial infarction: Teneligliptin (Brand name: Tenilia), an anti-hyperglycemic medication used in the treatment of TIIDM, decreases IRF3, GM-CSF (Granulocyte-macrophage colony-stimulating factor) and GRK2(G protein-coupled receptor kinase) expression, inhibits undue leukocyte activation and invasion, suppresses recruitment of inflammatory cells, inhibits ventricular dilation, and promotes heart repair and survival via up regulation of its target gene, 21/February/2019, 12.09 am
Molecular therapy for attenuating pathogenesis-associated with Myocardial infarction: Teneligliptin (Brand name: Tenilia), an anti-hyperglycemic medication used in the treatment of TIIDM, decreases IRF3, GM-CSF (Granulocyte-macrophage colony-stimulating factor) and GRK2(G protein-coupled receptor kinase) expression, inhibits undue leukocyte activation and invasion, suppresses recruitment of inflammatory cells, inhibits ventricular dilation, and promotes heart repair and survival via up regulation of its target gene, 21/February/2019, 12.09 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A recent study from Department of Systems Biology, Harvard Medical School, Boston, Massachusetts, USA; and Cardiovascular Research Center, Massachusetts General Hospital and Harvard Medical School, Boston,…

read more

Combinatorial therapy for metastasis: A pharmacological mixture Simvastatin and Navitoclax/ABT-263 (SAN) inhibits the expression of IL-6/8, decreases the expression of downstream molecules WASF3 and Arp2/3, suppresses tumor cell migration, reduces metastasis and prolongs survival via up regulation of its target gene, 20/February/2019, 12.54 am
Combinatorial therapy for metastasis: A pharmacological mixture Simvastatin and Navitoclax/ABT-263 (SAN) inhibits the expression of IL-6/8, decreases the expression of downstream molecules WASF3 and Arp2/3, suppresses tumor cell migration, reduces metastasis and prolongs survival via up regulation of its target gene, 20/February/2019, 12.54 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A study from Department of Chemical and Biomolecular Engineering, The Johns Hopkins University, Baltimore, Maryland 21218, USA; Johns Hopkins Physical Sciences-Oncology Center, The Johns Hopkins University, Baltimore, Maryland…

read more
Start Typing